Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients

2016 ◽  
Vol 55 (11) ◽  
pp. 1381-1394 ◽  
Author(s):  
Morgane Caulet ◽  
Thierry Lecomte ◽  
Olivier Bouché ◽  
Jérôme Rollin ◽  
Valérie Gouilleux-Gruart ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Progression Free Survival ◽  
Free Survival ◽  
Colorectal Cancer Patients

scholarly journals Metastatic colorectal cancer patients who achieved long progression-free survival by regorafenib or TAS-102 therapy

2016 ◽  
Vol 27 ◽  
pp. vii78
Author(s):  
Yosuke Kito ◽  
Satoshi Hamauchi ◽  
Kentaro Yamazaki ◽  
Azusa Komori ◽  
Toshiki Masuishi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Progression Free Survival ◽  
Free Survival ◽  
Colorectal Cancer Patients

Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients

2011 ◽  
Vol 17 (19) ◽  
pp. 6329-6337 ◽  
Author(s):  
Nicolas Azzopardi ◽  
Thierry Lecomte ◽  
David Ternant ◽  
Michelle Boisdron-Celle ◽  
Friedrich Piller ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Progression Free Survival ◽  
Free Survival ◽  
Colorectal Cancer Patients

scholarly journals Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients

Cancers ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 1856 ◽  
Author(s):  
Ondrej Fiala ◽  
Pavel Ostasov ◽  
Ondrej Sorejs ◽  
Vaclav Liska ◽  
Tomas Buchler ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Antihypertensive Drugs ◽  
Beta Blockers ◽  
Progression Free Survival ◽  
Antiangiogenic Agents ◽  
Free Survival ◽  
Colorectal Cancer Patients ◽  
The Impact

Background: Beta-adrenergic signalling plays an important role in several cancer-related processes, including angiogenesis. The impact of beta-blocker use on prognosis of cancer patients treated with antiangiogenic agents is unclear. The aim of this study was to evaluate the association between the incidental use of beta-blockers and the outcomes of patients with metastatic colorectal cancer (mCRC) treated with bevacizumab-based therapy. Methods: Clinical data from 514 mCRC patients treated with bevacizumab between 2005 and 2019 were analysed retrospectively. The association of progression-free survival (PFS) and overall survival (OS) with the incidental use of beta-blockers and other common antihypertensive drugs was assessed. Results: The median PFS and OS for patients using beta-blockers was 11.40 (95% confidence interval (CI) 10.10–13.61) months and 26.8 (95% CI 22.2–32.2) months compared with 8.30 (95% CI 7.80–9.57) and 21.0 (95% CI 17.8–23.8) months for patients not using beta-blockers (p = 0.006 and p = 0.009, respectively). In the Cox multivariate analysis, the use of beta-blockers was a significant factor predicting both PFS (hazard ratio (HR) = 0.763 (95% CI 0.606–0.960), p = 0.021) and OS (HR = 0.730 (95% CI 0.560–0.951), p = 0.020). Conclusions: The results of the present retrospective study suggest that there is a significant association between the use of beta-blockers and favourable outcomes of mCRC patients treated with bevacizumab-based therapy.

scholarly journals Statin Use Is Not Associated with Improved Progression Free Survival in Cetuximab Treated KRAS Mutant Metastatic Colorectal Cancer Patients: Results from the CAIRO2 Study

PLoS ONE ◽  
2014 ◽  
Vol 9 (11) ◽  
pp. e112201 ◽  
Author(s):  
Lisanne L. Krens ◽  
Lieke H. J. Simkens ◽  
Jara M. Baas ◽  
Els R. Koomen ◽  
Hans Gelderblom ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Progression Free Survival ◽  
Free Survival ◽  
Colorectal Cancer Patients ◽  
Statin Use
Sign in / Sign up

Export Citation Format

Share Document